XDXinzhou Deng

Xinzhou Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinzhou Deng has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Ao Liu

    Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China

    1 shared publication
  • Chengyang Huang

    Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China

    1 shared publication
  • Chuanyi Zhang

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China

    1 shared publication
  • Feng Peng

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China

    1 shared publication
  • Jingjing Chai

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China

    1 shared publication
  • Li Qiu

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China

    1 shared publication

Latest Publications

  • Open Access

    Construction and investigation of β3GNT2-associated regulatory network in esophageal carcinoma

    by Zhiguo Luo, Qing Hu, Yuanhui Tang, Yahui Leng, Tian Tian, Shuangyue Tian, Chengyang Huang, Ao Liu, Xinzhou Deng, Li Shen

    Glycosyltransferases play a crucial role in various cancers. β1, 3-N-acetylglucosaminyltransferase 2, a polylactosamine synthase, is an important member of the glycosyltransferase family. However, the biological function and regulatory mechanism of β3GNT2 in esophageal carcinoma (ESCA) is still poorly understood. The Cancer Genome Atlas and Genotype-Tissue Expression databases were used for gene expression and prognosis analysis. Quantitative real-time PCR, Western blot, and immunohistochemistry were performed to detect the expression of β3GNT2 in ESCA cell lines and tissues. In vitro assays and xenograft tumor models were utilized to evaluate the impact of β3GNT2 on ESCA progression. The downstream effectors and upstream regulators of β3GNT2 were predicted by online software and verified by functional experiments. We found that β3GNT2 was highly expressed in ESCA tissues and positively correlated with poor prognosis in ESCA patients. β3GNT2 expression was closely associated with the tumor size, TNM stage, and overall survival of ESCA patients. Functionally, β3GNT2 promoted ESCA cell growth, migration, and invasion in vitro, as well as tumorigenesis in vivo. Mechanistically, β3GNT2 knockdown decreased the expression of the polylactosamine on EGFR. Knockdown of β3GNT2 also inhibited the JAK/STAT signaling pathway. Meanwhile, the JAK/STAT inhibitor could partly reverse the biological effects caused by β3GNT2 overexpression. Moreover, β3GNT2 expression was positively regulated by CREB1 and negatively regulated by miR-133b. Both CREB1 and miR-133b was involved in the β3GNT2-mediated ESCA progression. Our study, for the first time, reveals the importance of β3GNT2 in ESCA progression and offers a potential therapeutic target for ESCA.


  • PAG1 promotes the inherent radioresistance of laryngeal cancer cells via activation of STAT3

    by Li Shen, Qing Ke, Jingjing Chai, Chuanyi Zhang, Li Qiu, Feng Peng, Xinzhou Deng, Zhiguo Luo